• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SciSparc Ltd.

    4/28/25 8:56:08 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    S-8 1 ea0239224-s8_scisparc.htm REGISTRATION STATEMENT


    As filed with the Securities and Exchange Commission on April 28, 2025

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    SCISPARC LTD.

    (Exact name of registrant as specified in its charter)

     

    State of Israel   Not applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    20 Raul Wallenberg Street, Tower A
    Tel Aviv, Israel
      6971916
    (Address of Principal Executive Offices)   (Zip Code)

      

    SciSparc Ltd. 2023 Share Incentive Plan

    (Full title of the plan)

     

    Puglisi & Associates

    850 Library Ave., Suite 204

    Newark, DE 19711

    Tel: (302) 738-6680

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Shachar Hadar
    Meitar | Law Offices
    16 Abba Hillel Road
    Ramat Gan, 5250608, Israel
    Tel: +972 (3) 610-3100 
     
     

    Oded Har-Even, Esq.

    Howard Berkenblit, Esq.

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, NY 10020

    (212)-660-3000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☐
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed to register an additional 1,000,000 ordinary shares, no par value (the “Ordinary Shares”), of SciSparc Ltd. (the “Registrant,” “we,” “our” or “us”) issuable pursuant to the SciSparc Ltd. 2023 Share Incentive Plan (the “2023 Plan”).

     

    On April 1, 2024, we filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-8 (File No. 333-278437) registering 1,013,787 Ordinary Shares issuable under the 2023 Plan.

     

    Pursuant to Instruction E of Form S-8, the contents of our prior registration statement on Form S-8 (File No. 333-278437) are incorporated herein by reference, and the information required by Part II is omitted, except as supplemented by the information set forth below.

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information required in Part I of this Registration Statement have been or will be sent or given to participating employees as specified in Rule 428(b)(1) under the Securities Act of 1933, as amended, or the Securities Act, in accordance with the rules and regulations of the Commission. Such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    in the Plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended.

     

    1

     

     

    PART II

     

    Information Required in the Registration Statement

     

    Item 3. Incorporation of Documents by Reference.

     

    We hereby incorporate by reference the following documents (or portions thereof) that we have filed with or furnished to the Commission:

     

    (a)Our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on April 24, 2025 (File No. 001-38041) (the “Annual Report”);

     

    (b)The Registrant’s Reports on Form 6-K filed with the Commission on April 25, 2025 (with respect to the first three paragraphs and the section titled “Forward-Looking Statement Disclaimer” in the press release attached as Exhibit 99.1 to the Report on Form 6-K); and

     

    (c)The description of our securities contained in our Form 8-A filed on December 20, 2021 (File No. 001-38041), including as amended by Exhibit 2.1 to the Annual Report and any further amendment or report filed for the purpose of updating such description.

     

    All other documents filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, and, to the extent designated therein, Reports of Foreign Private Issuer on Form 6-K furnished by us to the Commission that are identified in such forms as being incorporated into this Registration Statement, in each case, subsequent to the effective date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered under the Registration Statement have been sold, or deregistering all securities then remaining unsold, are also incorporated herein by reference and shall be a part hereof from the date of the filing or furnishing of such documents.

     

    Any statement contained herein or in a document all or a portion of which is incorporated or deemed incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Exhibit
       
    4.1   Amended and Restated Articles of Association of the Registrant (1)
    5.1*   Opinion of Meitar | Law Offices as to the legality of the Registrant’s Ordinary Shares
    23.1*   Consent of Kost, Forer, Gabbay and Kasierer, a member of Ernst & Young Global
    23.2*   Consent of Meitar | Law Offices (included in Exhibit 5.1)
    24.1*   Power of Attorney (included on the signature page of this Registration Statement)
    99.1   SciSparc Ltd. 2023 Share Incentive Plan (2)
    107.1*   Filing Fee Table

     

    (1)Incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form F-3 (File No. 333-269839), filed with the Commission on February 16, 2023.

     

    (2)Incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form F-1 (File No. 333-277394), filed with the Commission on February 27, 2024.

     

    *Filed herewith.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the United States, on this 28th day of April, 2025.

     

      SCISPARC LTD.
         
      By: /s/ Oz Adler
      Name:  Oz Adler
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints Oz Adler, his or her true and lawful attorney-in-fact and agent, with full power to act separately and full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto the said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Oz Adler   Chief Executive Officer and Chief Financial Officer   April 28, 2025
    Oz Adler   (Principal Executive Officer and Principal Accounting Officer)    
             
    /s/ Amitay Weiss   Chairman of the Board of Directors   April 28, 2025
    Amitay Weiss        
             
    /s/ Amnon Ben Shay   Director   April 28, 2025
    Amnon Ben Shay        
             
    /s/ Alon Dayan   Director   April 28, 2025
    Alon Dayan        
             
    /s/ Moshe Revach   Director   April 28, 2025
    Moshe Revach        
             
    /s/ Itschak Shrem   Director   April 28, 2025
    Itschak Shrem        
             
    /s/ Liat Sidi   Director   April 28, 2025
    Liat Sidi        
             
    /s/ Lior Vider   Director   April 28, 2025
    Lior Vider        

     

    II-2

     

     

    AUTHORIZED REPRESENTATIVE:

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of SciSparc Ltd. has signed this registration statement on April 28, 2025.

     

      PUGLISIGI & ASSOCIATES

     

      By: /s/ Donald J. Puglisi
      Name:  Donald J. Puglisi
      Title: Managing Director

     

     

    II-3

     

     

    Get the next $SPRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    SEC Filings

    See more
    • Amendment: SEC Form F-4/A filed by SciSparc Ltd.

      F-4/A - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 7:11:58 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by SciSparc Ltd.

      S-8 - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 8:56:08 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      4/25/25 8:19:42 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Financials

    Live finance-specific insights

    See more
    • SciSparc Adopts Limited Duration Shareholder Rights Plan

      TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

      11/28/23 8:55:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

      SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

      11/22/23 7:42:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

      Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

      9/27/23 7:58:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Leadership Updates

    Live Leadership Updates

    See more
    • SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

      As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

      5/30/23 8:40:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

      JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

      6/15/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

      Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

      3/30/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Subject)

      3/6/24 5:02:18 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Filed by)

      12/13/22 6:22:30 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

      SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

      5/9/22 4:08:30 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

      TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide ("PEA"). This innovative combination aims to address the complex neurobiological and psych

      4/25/25 7:59:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office ("KIPO"). The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide ("PEA") for the treatment of cocaine addiction. The patent is based on preclinical trial results led by P

      3/10/25 7:45:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea's official patent and intellectual property authority. The patent covers the Company's innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Mu

      3/10/25 7:27:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care